908 Devices Inc. · NASDAQ:MASS
908 Devices — TD Cowen's 45th Annual Healthcare Conference (March 2025)
8 slides from 908 Devices's conference presentation, Mar 5, 2025
Slide 1: Strategic Transformation Realized
Strategic Transformation Realized MARCH 5th 2025
Slide 2: Forward looking statements / Non-GAAP financial measures
Forward looking statements / Non-GAAP financial measures This presentation and the accompanying oral presentation (this “presentation”) contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securit
Slide 3: We create next-generation analytical tools for point-of-need use
We create next-generation analytical tools, designed for ‘point-of-need’ use in vital health and safety contexts BROAD USE CASES Fentanyl / Corrections Fire / Law Pharma Drugs-of-Abuse & Rehabilitation Enforcement OEM Toxic VOCs / Customs / Safety Industrial Pesticides Cancer Postal Inspection & Def
Slide 4: Strategic Transformation Realized
Strategic Transformation Realized Sharpens focus, strengthens financials, and accelerates profitability 1 2 Focus on Growth Market Divest Biopharma Shifting focus to high-growth handheld Selling the desktop portfolio to markets, aligning to secular tailwinds REPLIGEN for $70M cash (~6x multiple). in
Slide 5: Realizing a Strategic Transformation
Realizing a Strategic Transformation 1 YE 2023 2,422 Devices $38.2M 2023 52% 2023 -$30M 2023 $146M YE 2023 5
Slide 6: Realizing a Strategic Transformation
Realizing a Strategic Transformation 1 4 2 Y0 E 2 32- 0 220 23 4 2025 +25% INCREASE 3,015 @ YE 2024 +40% INCREASE $53M - $55M +11 to 15% YoY Mid-High 50% Range 2025 IMPROVED + Adj. EBITDA by Q4 2025 SECURED $110M+ YE 2025 6
Slide 7: Realizing a Strategic Transformation
Realizing a Strategic Transformation 1 4 6 YE 2023 2025 2026 & BEYOND MASSIVE OPPORTUNITY 20,000+ Device Opportunity ACCELERATION 20%+ Growth w/ 3 Catalysts IMPROVING YoY PROFITABLE Cash Flow Positive $110M+ 7
Slide 8: Realizing a Strategic Transformation
Realizing a Strategic Transformation IPO 2020 2027 $1.5B $2.5B TAM TAM 908 Devices 1 4 6 “2.0” YE 2023 2025 2026 & BEYOND • Reduced Customer Concentration • Higher Base + Accelerated Growth IMPROVING YoY • Stronger Margins • Improving OPEX Productivity • Profitable w/ Unlimited Runway 8
908 Devices — TD Cowen's 45th Annual Healthcare Conference (March 2025) on 6ix